Semaglutide and Metformin Compared to Metformin Alone for Weight Gain from Antipsychotics in People with Type 2 Diabetes

61.29% of patients receiving combination therapy achieved weight loss ≥ 5% from baseline compared to 38.7% in the monotherapy group.

• Combination therapy with semaglutide and metformin is associated with a higher rate of significant weight loss in patients with Type 2 Diabetes Mellitus on antipsychotics.
• The difference in the primary outcome of weight loss ≥ 5% between the two groups was statistically significant (p = 0.04).
• The observed BMI % difference from baseline was -5.58% for the combination group and -3.88% for the monotherapy group, though this difference was not statistically significant (p = 0.129).
• A notable reduction in HbA1c % from baseline was found in the combination group (-0.9%) compared to the monotherapy group (0.14%), with a statistically significant difference (p = 0.007).
• The findings suggest that combination therapy may be more effective for managing weight in this population, warranting further research.

Simplified